The following is a summary of “Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trial,” published in the February 2025 issue of Nephrology Dialysis ...
The pharmacokinetics of this compound are similar in study subjects with diabetes and in those without. Age, gender, body weight, race, administration with food, or mild renal impairment do not ...
Dapagliflozin and canagliflozin are the first agents of this class, approved from the European Medicine Agency and FDA, respectively. Given the high importance of diabetes, the glucose homeostasis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback